163
Participants
Start Date
December 20, 2012
Primary Completion Date
November 26, 2015
Study Completion Date
January 29, 2025
nilotinib
"Nilotinib was dosed by weight or body surface area.~Nilotinib 300 mg BID or 400 mg BID was be administered orally at approximately 12 hour intervals, and must not have been taken with food. The capsules were to be swallowed whole with water.~No food should have been consumed for at least 2 hours before the dose was taken and no additional food should have been consumed for at least one hour after the dose was taken. Patients were also allowed to enter this study on the same dose they were taking prior to study entry. Patients who required permanent dose reduction from their original starting dose were to be allowed to enter this study on the same dose only if the patient maintained this dose for a minimum of 6 months prior to study entry."
Novartis Investigative Site, Antwerp
Novartis Investigative Site, Box Hill
Novartis Investigative Site, Adelaide
Novartis Investigative Site, Berlin
Novartis Investigative Site, Potsdam
Novartis Investigative Site, Athens
St Agnes Hospital, Baltimore
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Grenoble
Novartis Investigative Site, San Cristóbal de La Laguna
Novartis Investigative Site, Santander
Novartis Investigative Site, Seville
Indiana Blood and Marrow Institute, Beech Grove
Novartis Investigative Site, Vandœuvre-lès-Nancy
Novartis Investigative Site, Monterrey
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Lyon
Novartis Investigative Site, Heilbronn
Novartis Investigative Site, Ulm
USC Kenneth Norris Comprehensive Cancer Center, Los Angeles
Compass Oncology, Vancouver
Novartis Investigative Site, Moscow
Novartis Investigative Site, Singapore
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Chiba
Novartis Investigative Site, Haifa
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Ramat Gan
University of Texas Medical Branch, Galveston
Novartis Investigative Site, CABA
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, Goiânia
Novartis Investigative Site, Belo Horizonte
Novartis Investigative Site, Rio de Janeiro
Novartis Investigative Site, Rio de Janiero
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, Campinas
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Québec
Novartis Investigative Site, Athens
Novartis Investigative Site, Larissa
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Narita
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Kurume
Novartis Investigative Site, Akita
Novartis Investigative Site, Aomori
Novartis Investigative Site, Krakow
Novartis Investigative Site, Gdansk
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Seoul
Novartis Investigative Site, Badalona
Novartis Investigative Site, Alicante
Novartis Investigative Site, Liverpool
Novartis Investigative Site, Nottingham
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY